Epidemiology and Risk Factors of Urothelial Bladder Cancer

Burger, Maximilian; Catto, James W.F.; Dalbagni, Guido; Grossman, H. Barton; Herr, Harry W.; Karakiewicz, Pierre I.; Kassouf, Wassim; Kiemeney, Lambertus A.; Vecchia, Carlo La; Shariat, Shahrokh F.; Lotan, Yair

doi:10.1016/j.eururo.2012.07.033

Cited by 1,738 publications

(1,363 citation statements)

References 49 publications

Supporting

Mentioning

1,229

Contrasting

Unclassified

Order By: Relevance

“…In this study we focus upon urothelial urinary bladder cancer (UBC), which in the western world is the fourth most common cancer in men and ninth in women [19]. The non‐muscle‐invasive UBC is treated routinely using Bacillus Calmette–Guerin (BCG) instillation in the bladder, indicating a substantial level of immunogenicity in this cancer [20].…”

Section: Introductionmentioning

confidence: 99%

Tissue-resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer

Hartana

Bergman

Broomé

et al. 2018

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryTissue‐resident memory T (TRM) cells are CD8+ T lymphocytes that reside in the tissues, including tumours. This T cell subset possesses a magnitude of cytotoxicity, but its epigenetic regulation has not been studied. Here, we investigate the impact of perforin DNA methylation in TRM cells and correlate it with their functional potential. Fifty‐three urothelial urinary bladder cancer (UBC) patients were recruited prospectively. The DNA methylation status of the perforin gene (PRF1) locus in TRM cells was investigated by pyrosequencing. Flow cytometry with ViSNE analysis and in‐vitro stimulation were used to evaluate TRM cell phenotypes. We discovered that tumour TRM cells have low DNA methylation in the PRF1 locus (32·9% methylation), which corresponds to increased numbers of perforin‐expressing TRM cells. Surprisingly, programmed cell death 1 (PD‐1) expression is high in tumour TRM cells, suggesting exhaustion. Following interleukin‐15 and T cell receptor stimulation, perforin and T‐bet expressions are enhanced, indicating that TRM cells from tumours are not terminally exhausted. Moreover, a high number of TRM cells infiltrating the tumours corresponds to lower tumour stage in patients. In conclusion, TRM cells from UBC tumours are epigenetically cytotoxic with signs of exhaustion. This finding identifies TRM cells as potential new targets for cancer immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Tissue-resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer

Hartana

Bergman

Broomé

et al. 2018

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…An estimated 386,300 new cases and 150,200 deaths from bladder cancer occurred in 2008 worldwide (Jemal et al, 2011). Although the etiology of this disease remains largely elusive, cigarette smoking, occupational exposure to arylamines and schistosomal infection are generally considered possible risk factors for this cancer (Murta-Nascimento et al, 2007;Jemal et al, 2011;Burger et al, 2012). In addition, increasing evidence suggests a significant influence of genetic predisposition on bladder incidence (Burger et al, 2012); the role of genetic factors in the etiology of bladder cancer is estimated to be about 31% (Lichtenstein et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

“…Although the etiology of this disease remains largely elusive, cigarette smoking, occupational exposure to arylamines and schistosomal infection are generally considered possible risk factors for this cancer (Murta-Nascimento et al, 2007;Jemal et al, 2011;Burger et al, 2012). In addition, increasing evidence suggests a significant influence of genetic predisposition on bladder incidence (Burger et al, 2012); the role of genetic factors in the etiology of bladder cancer is estimated to be about 31% (Lichtenstein et al, 2000). NAD(P)H:quinone oxidoreductase 1 (NQO1), also known as diphtheria toxin diaphorase (DT-diaphorase), is an obligate two-electron reductase, which reduces reactive quinones to less reactive and less toxic hydroquinones .…”

Section: Introductionmentioning

confidence: 99%

The NQO1 rs1800566 Polymorphism and Risk of Bladder Cancer: Evidence from 6,169 Subjects

Guo¹,

Feng²

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…1 Although the 5-year survival for NMIBC is more than 90%, the survival period is not disease-free. 2,3 After the initial transurethral resection (TUR), about half of NMIBC patients are at risk for disease recurrence and, to lesser extent, progression to muscle-invasive disease.…”

Section: Introductionmentioning

confidence: 99%

“…2,3 After the initial transurethral resection (TUR), about half of NMIBC patients are at risk for disease recurrence and, to lesser extent, progression to muscle-invasive disease. 1,3 To reduce recurrence and progression, adjuvant intravesical therapy is given and recommended by European Association of Urology (EAU) guidelines. 3 Instillation of bacillus Calmette-Guérin (BCG) is considered more effective than chemotherapy for NMIBC, representing the first-line option in high-risk patients.…”

Section: Introductionmentioning

confidence: 99%

Intravesical bacillus Calmette-Guérin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer

Ekin¹,

Akarken

Zorlu³

et al. 2015

CUAJ

View full text Add to dashboard Cite

Introduction: Patients with high-risk non-muscle invasive bladder cancer (NMIBC) need adjuvant intravesical treatment after surgery. Although bacillus Calmette-Guérin (BCG) is highly effective, new adjuvant treatments to decrease recurrences and toxicity have been studies. We performed a retrospective propensity score-matched study to compare the efficacy of BCG and chemohyperthermia (C-HT). Methods: We included 1937 patients diagnosed with bladder cancer between January 2004 and January 2014. The primary efficacy endpoint was recurrence-free interval. Patients treated with C-HT were matched with patients treated with BCG using propensity score-matched analysis. Cox-regression models were used to estimate the association between intravesical treatments and the presence of recurrence and progression. Results: Of the 710 patients treated with intravesical treatments, 40 and 142 were eligible for inclusion in C-HT and BCG groups, respectively. Following case matching, there were no differences in patient or tumour characteristics between treatment groups. The 2-year recurrence-free interval in C-HT and BCG groups were 76.2% and 93.9%, respectively (p = 0.020). C-HT treatment (hazard ratio [HR] 5.42; 95% confidence interval [CI] 1.11-26.43; p = 0.036) and high-grade tumour (HR 4.60; 95% CI 1.01-20.88; p = 0.048) are associated with an elevated odds of tumour recurrence. In multivariate Cox-regression analysis, there was no significant difference between C-HT and BCG in the odds of recurrence (p = 0.054). There were no differences in progression between C-HT and BCG. Conclusion: C-HT is not as effective treatment as BCG in high-risk NMIBC patients who are BCG-naive. Although, there were no significant difference in the odds of recurrence, recurrence-free interval is significantly improved by the administration of BCG.

show abstract

Epidemiology and Risk Factors of Urothelial Bladder Cancer

Cited by 1,738 publications

References 49 publications

Tissue-resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer

Tissue-resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer

The NQO1 rs1800566 Polymorphism and Risk of Bladder Cancer: Evidence from 6,169 Subjects

Intravesical bacillus Calmette-Guérin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer

Contact Info

Product

Resources

About